### Comment:
I agree with you as t1d. My intuition is saying very low market for this drug. When trying to improve ha1c's, there's a multitude of steps to take which don't carry the side-effects of these inhibitors. They seem like a last resort for individuals with highly sensitive blood glucose responses. CGM tech has greater a1c reductions, but without these risks.

### REPLY:
SLGT2s are gangbusters for heart failure.  Clinical trial data demonstrates mortality benefit.  
  
 As DM drugs, I almost never prescribe them. Triple oral therapy has only received ADA backing and usually by that time, they need insulin.

### END.